Previous 10 | Next 10 |
Bristol-Myers Squibb (NYSE: BMY ) and bluebird bio (NASDAQ: BLUE ) have amended their existing co-promotion and co-development agreement related to CAR T immunotherapy bb2121. More news on: Bristol-Myers Squibb Company, bluebird bio, Inc., Healthcare stocks news, Stocks on the move, ...
- Bristol Myers Squibb to buy out its ex-U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – - bluebird to hold conference call and webcast today, May ...
bluebird bio (NASDAQ: BLUE ): Q1 GAAP EPS of -$3.64 beats by $0.41 . More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021 - - Completed submission with Bristol Myers Squibb of Biologics License Application (BLA) for anti-BCMA CAR T cell therapy idecabtag...
bluebird bio (NASDAQ: BLUE ) is scheduled to announce Q1 earnings results on Monday, May 11th, before market open. The consensus EPS Estimate is -$4.05 (-35.5% Y/Y) and the consensus Revenue Estimate is $8M (-36.0% Y/Y). Over the last 2 years, BLUE has beaten EPS estimates 0% of the ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
-Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated resul...
bluebird bio (NASDAQ: BLUE) is a biotech company that focuses on gene editing. This technology seeks to treat diseases by replacing the defective genes responsible for them with their healthy counterparts. Year to date, shares of Bluebird are down by 33.9%, which is significantly worse than ...
bluebird bio, Inc. (NASDAQ: BLUE) today announced it will hold a conference call to discuss first quarter 2020 financial results and business updates on Monday, May 11 at 8:00 am ET. Investors may listen to the call on May 11, 2020 at 8:00 am ET by dialing (844) 825-4408 from locations in...
In this episode of Rule Breaker Investing , Motley Fool co-founder David Gardner and Motley Fool analysts Karl Thiel and Maria Gallagher review three Five-Stock Samplers. Learn about their businesses, why they went up or down, and what lessons you can take away from this review so that you ca...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...